Advisors Capital Management LLC Has $37.48 Million Stock Holdings in Thermo Fisher Scientific Inc. $TMO

Key Points

• Advisors Capital Management cut its stake in Thermo Fisher by 44.5%, selling 51,865 shares and finishing the quarter with 64,680 shares worth $37.48 million.
• Thermo Fisher beat Q1 estimates with $5.44 adjusted EPS (vs. $5.25 consensus) and $11.01B revenue (up 6.2% y/y), and management raised FY2026 EPS guidance to $24.64–$25.12.
• Despite the beat, the stock faced selling pressure over muted organic growth and analyst target cuts; insiders (including the EVP and CEO) sold shares, institutional ownership is high at 89.23%, and the company raised its quarterly dividend to $0.47 ($1.88 annualized).

Advisors Capital Management LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO - Free Report) by 44.5% during the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 64,680 shares of the medical research company's stock after selling 51,865 shares during the period. Advisors Capital Management LLC's holdings in Thermo Fisher Scientific were worth $37,479,000 at the end of the most recent quarter.

Several other hedge funds have also added to or reduced their stakes in the business. Golden State Equity Partners increased its position in Thermo Fisher Scientific by 1.4% during the 4th quarter. Golden State Equity Partners now owns 2,634 shares of the medical research company's stock valued at $1,526,000 after purchasing an additional 37 shares during the period. Stockman Wealth Management Inc. acquired a new stake in Thermo Fisher Scientific during the 4th quarter valued at approximately $224,000. Vanguard Group Inc. increased its position in Thermo Fisher Scientific by 0.9% during the 4th quarter. Vanguard Group Inc. now owns 34,133,702 shares of the medical research company's stock valued at $19,778,774,000 after purchasing an additional 288,296 shares during the period. Munich Reinsurance Co Stock Corp in Munich increased its position in Thermo Fisher Scientific by 60.1% during the 4th quarter. Munich Reinsurance Co Stock Corp in Munich now owns 62,250 shares of the medical research company's stock valued at $36,320,000 after purchasing an additional 23,375 shares during the period. Finally, Riverbend Wealth Management LLC increased its position in Thermo Fisher Scientific by 6.6% during the 4th quarter. Riverbend Wealth Management LLC now owns 806 shares of the medical research company's stock valued at $467,000 after purchasing an additional 50 shares during the period. 89.23% of the stock is currently owned by institutional investors and hedge funds.

Thermo Fisher Scientific Price Performance

Thermo Fisher Scientific stock opened at $469.27 on Friday. The stock has a market capitalization of $174.39 billion, a price-to-earnings ratio of 25.80, a PEG ratio of 2.41 and a beta of 0.97. Thermo Fisher Scientific Inc. has a 52-week low of $385.46 and a 52-week high of $643.99. The stock's 50 day moving average price is $499.11 and its two-hundred day moving average price is $549.52. The company has a debt-to-equity ratio of 0.77, a quick ratio of 1.53 and a current ratio of 1.53.

Thermo Fisher Scientific (NYSE:TMO - Get Free Report) last posted its quarterly earnings results on Thursday, April 23rd. The medical research company reported $5.44 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $5.25 by $0.19. Thermo Fisher Scientific had a return on equity of 16.86% and a net margin of 15.15%.The firm had revenue of $11.01 billion for the quarter, compared to analysts' expectations of $10.86 billion. During the same period in the prior year, the business earned $5.15 EPS. The company's revenue for the quarter was up 6.2% compared to the same quarter last year. Thermo Fisher Scientific has set its FY 2026 guidance at 24.640-25.120 EPS. On average, equities analysts predict that Thermo Fisher Scientific Inc. will post 24.71 earnings per share for the current year.

Thermo Fisher Scientific Increases Dividend

The company also recently announced a quarterly dividend, which was paid on Wednesday, April 15th. Investors of record on Friday, March 13th were issued a $0.47 dividend. The ex-dividend date was Friday, March 13th. This represents a $1.88 dividend on an annualized basis and a dividend yield of 0.4%. This is an increase from Thermo Fisher Scientific's previous quarterly dividend of $0.43. Thermo Fisher Scientific's dividend payout ratio (DPR) is 10.34%.

More Thermo Fisher Scientific News

Here are the key news stories impacting Thermo Fisher Scientific this week:

• Positive Sentiment: Q1 results beat expectations — Thermo Fisher reported $5.44 adjusted EPS vs. ~$5.25 consensus and revenue of $11.01B (up ~6.2% y/y), showing the company still delivered above-street top- and bottom-line results. Reuters: Thermo Fisher posts quarterly results beat
• Positive Sentiment: Full-year guidance updated — Management set FY2026 EPS guidance of $24.64–$25.12 and raised its outlook, which supports longer-term earnings visibility even if organic growth is uneven. Yahoo: Thermo Fisher Raises 2026 Outlook
• Neutral Sentiment: Analyst reactions mixed but generally constructive — Several firms kept buy/outperform ratings while trimming targets (Stifel: $700->$600; Robert W. Baird: $653->$639), signaling continued confidence in the company’s fundamentals despite the pullback. Benzinga / The Fly: PT cuts
• Neutral Sentiment: Analyst voices emphasize long-term opportunity — Some analysts (e.g., TD Cowen, William Blair) reiterated Buy ratings, pointing to core growth drivers and structural demand (biopharma services, lab products) that support recovery later in the year. TipRanks: Analyst commentary
• Negative Sentiment: Market punished the stock on weak underlying growth and mixed segments — Despite the beat, investors focused on muted organic growth in the core business and uneven segment performance, which triggered a sharp intraday decline and premarket weakness. Yahoo: Why TMO Stock Is Nosediving
• Negative Sentiment: Broader sector & market pressure amplified the move — The mixed report pressured peers (e.g., 10x Genomics) and coincided with a softer tape for health care/tech stocks, adding to downward momentum. Yahoo: Peer impact (10x Genomics)

Insiders Place Their Bets

In related news, EVP Gianluca Pettiti sold 400 shares of the stock in a transaction on Monday, February 9th. The stock was sold at an average price of $541.20, for a total value of $216,480.00. Following the transaction, the executive vice president directly owned 20,752 shares in the company, valued at $11,230,982.40. This trade represents a 1.89% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, CEO Marc N. Casper sold 5,000 shares of the stock in a transaction on Wednesday, March 4th. The stock was sold at an average price of $512.40, for a total value of $2,562,000.00. Following the completion of the transaction, the chief executive officer owned 123,925 shares in the company, valued at approximately $63,499,170. This represents a 3.88% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. 0.33% of the stock is owned by company insiders.

Analyst Upgrades and Downgrades

A number of analysts have weighed in on TMO shares. UBS Group reissued a "neutral" rating and set a $615.00 target price on shares of Thermo Fisher Scientific in a research report on Friday, January 30th. Barclays decreased their target price on shares of Thermo Fisher Scientific from $650.00 to $625.00 and set an "overweight" rating for the company in a research report on Tuesday, April 14th. TD Cowen decreased their target price on shares of Thermo Fisher Scientific from $696.00 to $683.00 and set a "buy" rating for the company in a research report on Friday, January 30th. Weiss Ratings restated a "hold (c)" rating on shares of Thermo Fisher Scientific in a report on Wednesday, April 8th. Finally, Robert W. Baird cut their price target on Thermo Fisher Scientific from $653.00 to $639.00 and set an "outperform" rating on the stock in a report on Friday. Two research analysts have rated the stock with a Strong Buy rating, nineteen have issued a Buy rating and two have issued a Hold rating to the company's stock. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of "Buy" and an average target price of $625.55.

About Thermo Fisher Scientific

Thermo Fisher Scientific NYSE: TMO is a global provider of scientific instrumentation, reagents and consumables, software, and services that support research, clinical, and industrial laboratories. The company supplies analytical instruments and laboratory equipment, life sciences reagents and kits, specialty diagnostics, and a broad range of consumables used by researchers, clinicians, and manufacturers. Its offerings also include laboratory information management and data-analysis software, as well as service solutions such as instrument maintenance, validation, and logistics that help customers run complex workflows efficiently.

Thermo Fisher operates through multiple business areas that broadly cover life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services, including contract development and manufacturing for pharmaceutical and biotechnology companies.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.